



Review article

Breast cancer treatment and its effects on aging

Leslie Chang^{a,b}, Lauren S. Weiner^{a,c}, Sheri J. Hartman^{a,c}, Steve Horvath^{d,e}, Dilip Jeste^{f,g},
Paul S. Mischel^{h,i}, Deborah M. Kado^{a,b,g,*}

^a Departments of Family Medicine & Public Health, School of Medicine, University of California, San Diego, United States

^b Department of Internal Medicine, School of Medicine University of California, San Diego, United States

^c University of California San Diego, Moores Cancer Center, La Jolla, CA, United States

^d Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, United States

^e Department of Biostatistics, Fielding School of Public Health, University of California, Los Angeles, United States

^f Departments of Psychiatry & Neuroscience, University of California, San Diego, United States

^g Sam and Rose Stein Institute for Research on Aging, United States

^h Department of Pathology, School of Medicine, University of California, San Diego, United States

ⁱ Ludwig Institute for Cancer Research, University of California, San Diego, United States



ARTICLE INFO

Article history:

Received 10 April 2018

Received in revised form 11 June 2018

Accepted 16 July 2018

Available online 2 August 2018

Keywords:

Breast cancer

Aging

Senescence

p16(INKa)

Telomere length

Epigenetic clock

Tissue age

Cognitive decline

Physiological decline

ABSTRACT

Breast cancer is the most common cancer of women in the United States. It is also proving to be one of the most treatable. Early detection, surgical intervention, therapeutic radiation, cytotoxic chemotherapies and molecularly targeted agents are transforming the lives of patients with breast cancer, markedly improving their survival. Although current breast cancer treatments are largely successful in producing cancer remission and extending lifespan, there is concern that these treatments may have long lasting detrimental effects on cancer survivors, in part, through their impact on non-tumor cells. Presently, the impact of breast cancer treatment on normal cells, its impact on cellular function and its effect on the overall function of the individual are incompletely understood. In particular, it is unclear whether breast cancer and/or its treatments are associated with an accelerated aging phenotype. In this review, we consider breast cancer survivorship from the perspective of accelerated aging, and discuss the evidence suggesting that women treated for breast cancer may suffer from an increased rate of physical and cognitive decline that likely corresponds with underlying vulnerabilities of genome instability, epigenetic changes, and cellular senescence.

© 2018 Elsevier Ltd. All rights reserved.

Contents

1.	Introduction	347
2.	Clinical Manifestations of Advanced Physiologic Aging in Breast Cancer Survivors	347
2.1.	Breast Cancer Therapies and Physical Health	347
2.1.1.	Accelerated Reproductive Aging	347
2.1.2.	Compromised Cardiopulmonary Fitness	348
2.2.	Breast Cancer Therapies and Cognitive Decline	348
2.2.1.	Influence of Age on Models of Cognitive Decline After Breast Cancer.	348
2.2.2.	Breast Cancer Treatments and Self-reported and Objective Cognition	348
2.2.3.	Breast Cancer Treatments and Neuroimaging Findings	348
3.	Molecular Mechanisms of Normal Cellular Aging in Patients with Breast Cancer	351
3.1.	Telomere Attrition	351
3.2.	Cellular Energetics	351
3.3.	Genome Instability	351
3.4.	Epigenetic Alterations.	351

* Corresponding author at: Department of Family Medicine, Public Health and Internal Medicine, University of California, San Diego, United States.
E-mail address: dkado@ucsd.edu (D.M. Kado).

3.5. Suppressor Checkpoints for Cellular Senescence	352
3.6. Other Markers of Cellular Senescence	352
4. Concluding Remarks	352
Contributions	352
Conflicts of Interest	352
References	352

1. Introduction

Breast cancer is the most frequent cancer amongst women in the United States and the second leading cause of cancer death for women [1]. An estimated 250,000 new cases of invasive breast cancer are diagnosed each year in the United States [1]. Patients with breast cancer are surviving longer as early detection measures improve and as advances in breast cancer treatment lead to increasingly improved survival outcomes. The five-year survival has risen from 75% in 1976 to 91% in 2017 [1]. With increased overall life expectancies, long-term breast cancer survivors are at risk for manifesting features of accelerated aging, the underpinnings of which likely involve overlapping hallmarks of aging and cancer development [2, 3]. While multiple epidemiological studies have highlighted long-term health complications associated with breast cancer treatments, the molecular mechanisms that underlie these apparent elevated health risks in breast cancer survivors have yet to be well elucidated.

From a clinical standpoint, careful evaluation and management of long-term and late side effects in patients with breast cancer are emerging as a critical challenge, particularly for patients who have undergone chemotherapy and require long-term adjuvant treatment [4–7]. Impairments in physical and cognitive functioning following treatment can considerably impact survivors' quality of life (QOL) [8–10] and treatment decision-making [11, 12]. Thus, the overall objective of this review is to begin to merge together two crucial fields of study in relationship to breast cancer long-term survival: 1) clinical studies that provide insight into how treatment affects patient-

centered important health outcomes; and 2) laboratory studies that elucidate the underlying molecular mechanisms of aging, particularly in response to breast cancer treatments. While ground-breaking advances in breast cancer treatment and survival have occurred in the last 30 years, there is still a lot of room to further improve therapeutic protocols by better understanding treatment effects on the rates of normal cellular aging.

As shown in Fig. 1, any pharmacologic treatment, targeted or not, also affects normal cells. Because of intrinsic differences in the genomes, epigenomes and transcriptomes between tumor cells and normal tissues, along with shifts in cellular metabolism and inherent genome instability that occurs in most tumors, cancer cells and normal cells in the body may respond quite differently to pharmacologic treatments in ways that could have profound long-term impact on health [2, 3, 13]. Importantly, unlike cancer cells that frequently lose tumor suppressor proteins, active tumor suppressive checkpoints remain in most normal cells, potentially leading to cell senescence, and possibly associated treatment induced cellular and organ damage that could contribute to accelerated aging.

Here, we examine the clinical health outcomes in patients treated with breast cancer in the context of well-described cellular and molecular hallmarks of aging that are likely affected by breast cancer cytotoxic therapies- summarizing the current state of the field and providing recommendations for future studies.

2. Clinical Manifestations of Advanced Physiologic Aging in Breast Cancer Survivors

2.1. Breast Cancer Therapies and Physical Health

A number of studies of the physical, functional and cognitive changes following breast cancer diagnosis and treatment reveal a landscape of challenges experienced by breast cancer survivors. Although the potential contribution of accelerated aging to cancer initiation cannot be excluded [14, 15], the cumulative data indicate, unequivocally, that breast cancer treatments are associated with either transient or long-lasting physical dysfunction and an accelerated aging phenotype. Currently, the treatment associated accelerated aging phenotype is an inescapable consequence of life-saving therapy. However, understanding the processes that contribute to this phenotype could shed new light on potential interventions that mitigate, or possibly even eliminate these adverse long-term health effects.

2.1.1. Accelerated Reproductive Aging

Though the exact cellular mechanisms and their relation to what patients experience post-chemotherapy has not been well delineated, the clinical manifestations may in part result from accelerated physiologic aging. Perhaps the clearest example is treatment-induced reproductive aging. Young women experience unavoidable and irreversible amenorrhea, infertility, and early hormonally-induced menopause as a consequence of ovarian chemotoxicity. Age is the most relevant biological factor influencing chemotherapy related amenorrhea; however, type of chemotherapy and schedule of administration may influence premature ovarian failure [16]. While imperative to treat the breast cancer, the induction of early menopause may have other long-term




Fig. 1. Cytotoxic therapy effects on tumor versus normal cells.

implications. For example, in a large observational study of 16,251 women, later age of natural menopause and longer reproductive lifespan was significantly associated with increased longevity [17], suggesting that longer reproductive capacity may reflect more favorable cellular aging.

2.1.2. Compromised Cardiopulmonary Fitness

Cardiorespiratory fitness may be one of the best markers of physiological age that tends to decline over time, and evidence suggests that patients with breast cancer treated with adjuvant therapies may age more quickly. In a recent review of 27 breast cancer studies that included randomized controlled trials, exercise interventions or observational studies of cardiorespiratory fitness assessed by V02 max, there was a strong consensus that compared to pre-adjuvant therapy or healthy sedentary controls, those who had received adjuvant therapy had the worst performance [18].

Early clinical trials demonstrate that adjuvant chemotherapy, especially anthracyclines, can cause short-term cardiotoxicity; however, the clinical benefit of decreased annual breast cancer death rates by 20–38% are the reason for continued use [19–22]. Pre-treatment cardiac screening and dose adjustment have served to improve clinical outcomes with decreased cardiac toxicity, but there remain concerns about possible long-term cardiac sequelae. While some smaller studies suggested no long-term cardiac complications associated with anthracycline use, the largest to date of 43,338 women demonstrated an increased number of heart failure cases in older breast cancer survivors who received anthracyclines compared with other treatments [23]. Aromatase inhibitor therapy, which increases bone turnover and decreases bone mineral density, increases the risk of fractures and osteoporosis [24–27]. Peripheral neuropathy and neuropathic pain are other common chemotherapy related adverse effects and in particular, neuropathy may be very debilitating for older survivors as it may precipitate falls and fractures [28]. Taken together, an abundance of evidence suggests that some of the breast cancer therapies may increase the rate of physiological aging, with long-term adverse health consequences.

2.2. Breast Cancer Therapies and Cognitive Decline

Cognitive impairment is one of most common symptoms among breast cancer survivors [29–31]. Impairments can range from subtle to severe and last for up to 20 years following treatment [32–34]. While the high prevalence of cognitive impairment among breast cancer survivors is well documented, data are conflicting regarding the extent to which cognitive deficits are related to treatment. A summary of relevant studies of cognitive function and cognitive imaging in patients with breast cancer is provided (see Table 1) where the study findings have been compared and contrasted in different age groups, classified by outcome, treatment modality, and study design [33, 35–47]. A meta-analysis by Jim et al. [48] that analyzed results of 17 studies found cognitive deficits in verbal and visuospatial abilities in patients treated with chemotherapy. This is consistent with results of several previous meta-analyses reporting significant impairments across multiple domains among patients with cancer treated with chemotherapy [49–53]. However, some longitudinal studies have found weak or null associations between chemotherapy and objectively measured neurocognitive deficits or self-reported cognitive concerns [54, 55]. Likewise, evidence for a negative association between endocrine therapy and cognition is mixed [56–59], with at least one longitudinal study finding significant improvements in neurocognitive performance after completion of endocrine therapy [60] or both chemotherapy and endocrine therapy [61]. A recent prospective study found that while chemotherapy was linked to self-reported cognitive concerns, those who received aromatase inhibitors alone did not report clinically meaningful concerns [59]. Other research has shown that cognitive deficits are not limited to those undergoing adjuvant treatment. Some studies have found pre-

treatment impairments in objectively measured cognition [52, 62, 63]. A meta-analysis by Ono et al. [53] reported that levels of neurocognitive impairment in chemotherapy versus non chemotherapy treated patients did not significantly differ, providing evidence that factors other than treatment regimen may influence risk of cognitive impairment.

2.2.1. Influence of Age on Models of Cognitive Decline After Breast Cancer

Another important factor contributing to cognitive decline among cancer survivors may be increasing age [64, 65]. Aging is a strong risk factor for cancer [66] and older adults (age 65 years or older) represent the majority of cancer cases [67]. Cognitive impairment among breast cancer survivors may result from common risk factors for both the development of cancer and age-related cognitive decline [30, 68, 69]. Mandelblatt et al. [40] and Ahles et al. [70] describe two possible trajectories of cognitive impairment after cancer treatment relative to age-related decline. The *phase shift hypothesis* asserts that patients with cancer experience post-treatment cognitive declines that are slightly worse than those without cancer (or its treatment), but parallel the non-cancer population over time. Conversely, the *accelerated aging hypothesis* proposes that cancer and/or its treatment may accelerate normal aging, that is, patients with cancer may experience steeper and earlier declines in cognitive function compared to non-cancer populations [40, 70, 71]. Mandelblatt and colleagues [45] performed trajectory group analysis on a cohort of 1280 breast cancer survivors aged 65–91 years, assessed at six months post-treatment and annually for up to seven years. Over the follow-up period, 42.3% of survivors maintained high self-reported cognitive scores, 50.1% showed a phase shift pattern, and 7.6% showed accelerated decline. While age was not directly related to trajectory, age-related characteristics (having >2 vs ≤ 2) comorbidities and frailty, respectively) were associated more strongly with the accelerated aging group than the phase shift group. These results demonstrate that impairment among breast cancer survivors does not follow a uniform course but rather, may result from a complex synergy of age, comorbidities, cancer treatment, and cancer itself [72].

2.2.2. Breast Cancer Treatments and Self-reported and Objective Cognition

Although mixed, several studies show that breast cancer survivors exhibit impaired neurocognitive functioning compared to age-matched controls [40, 41, 73]. Breast cancer survivors have self-reported greater cognitive concerns compared to age-matched controls. In one of the largest published longitudinal studies of 581 breast cancer survivors, 36.5% of patients with breast cancer self-reported meaningful cognitive decline at six months, compared with only 13.6% of age-matched controls [74]. Longitudinal objective assessments are useful to determine whether age-associated declines in cognitive function in breast cancer survivors mirror adults without a cancer history and two that assessed patients six months or longer post-treatment reported that cancer survivors had lower scores on tests of processing speed and executive function [42, 75]. Taken together, these studies lend support to a prevailing hypothesis that cognitive impairments may be a symptom of accelerated aging caused by cancer and/or its treatments.

2.2.3. Breast Cancer Treatments and Neuroimaging Findings

Impairments observed through self-reported and objective neurocognitive testing are supported by evidence of physiological changes to the brain. Neuroimaging studies in breast cancer survivors have revealed structural alterations in both grey and white matter [76–78]. Functional changes including abnormal activation in frontal regions during cognitive tasks [35, 79] and reduced brain network resilience to attacks [38] have been reported in most, but not all studies [80]. fMRI changes in brain areas involved in executive control, memory, and emotional regulation were determined to be different between breast cancer survivors and healthy, age, education and intelligence matched controls [124]. However, the most compelling evidence of an ill effect from breast cancer treatments comes from magnetic resonance imaging (MRI) measurements of grey matter volume before and after

Table 1
Studies of cognitive function and aging among breast cancer survivors, by study design.

Authors	Study objectives	Study population	Mean age (SD, range)	N ^a	Treatments	Main study findings	Comments
Cross-sectional							
Conroy SK et al. [35]	Examine structural and functional effects of chemo and post-chemotherapy interval (PCI), and relationship of neuroimaging to neurocognitive testing, self-reported cognition, and oxidative DNA damage	24 breast cancer survivors, PCI mean 6.4, range 3–10 years 23 age- and education-matched controls	Cases: 57.8 (9.6) Controls: 61.2 (9.9)	47	100% C	PCI was positively correlated with structural and functional changes on MRI, which were related to neurocognitive performance. Compared to controls, breast cancer survivors had increased neurocognitive impairment (memory dysfunction), cognitive complaints, and DNA damage	Potential clinical significance of imaging results underscored by association with neurocognitive testing
De Ruiter MB et al. [36]	Assess brain activation and cognitive performance ~10 years after high-dose chemo	34 breast cancer survivors: 19 treated with chemo 15 not treated with chemo	Breast cancer survivors treated with chemo: 56.3 (5.5) Breast cancer survivors not treated with chemo: 58.2 (5.8)	34	Among those treated with chemo 100% H 100% R 100% S Among those not treated with chemo: 6.6% H 100% R 100% S	~10 years after treatment, high dose chemo was associated with long-term cognitive impairments including decreased responsiveness of brain regions related to executive functioning and memory encoding	Comparisons with non-breast cancer controls are necessary to assess trajectory of cognitive decline over time
Kesler SR et al. [37]	Examine differences in prefrontal-executive functioning between breast cancer survivors with and without treatment with chemotherapy compared to control, and to assess relationships between prefrontal cortex deficits and behavioral impairments	44 breast cancer survivors: 25 treated with chemo 19 not treated with chemo 18 healthy controls	Breast cancer survivors treated with chemo: 56.2 (7.8) Breast cancer survivors not treated with chemo: 58.1 (6.5) Controls: 55.6 (9.4)	62	Among those treated with chemo: 56% H 56% R Among those not treated with chemo: 53% H 68% R	Women treated with chemo had significant reduced left caudal lateral prefrontal cortex activation, increased perseverative errors, and reduced processing speed compared to non-chemo breast cancer survivors or controls. Older age was associated with greater executive functioning impairment in patients treated with chemo	Chemotherapy may interact with increasing age to accelerate cognitive decline
Kesler SR et al. [38]	Use brain network models to study the effects of chemo on white matter organization and connectivity, and brain network tolerance	34 breast cancer survivors 36 matched healthy controls	Cases: 56.9 (7.6, 43.8–72.7) Controls: 56.9 (8.2, 42.8–73.4)	70	100% C 60% H 80% R 100% S	Cases showed reduced brain network tolerance (brain resilience) to simulated neurodegeneration, which was associated with neurocognitive deficits. Despite larger overall impacts of attacks on brain network among cases, both groups experienced similar rate of decline.	Findings support phase shift (parallel) rather than accelerated decline among breast cancer survivors treated with chemo
Lange M et al. [39]	Assess cognitive functioning among elderly breast cancer patients before adjuvant treatment	123 breast cancer patients	70 (4.1, 65–83)	123	100% S	41% of patients had cognitive impairment before any adjuvant treatment, significantly higher than what is reported in normative data based on age and education. Proportion of patients reporting pre-treatment impairments was higher than published rates of pre-treatment impairments in younger survivors.	Older patients may be more sensitive to the effects of cancer on cognition, but longitudinal studies are needed to determine if cancer treatment accelerates normal cognitive aging
Mandelblatt JS et al. [40]	Determine if older breast cancer patients show cognitive impairment before systemic treatment	164 breast cancer patients (pre-treatment) 182 age-matched non-cancer controls	Cases: 68.1 (6.7, 60–98) Controls: 67.3 (6.5, 60–90)	346	100% S	No differences in unadjusted rates of neurocognitive impairment in breast cancer patients (14%) before systemic treatment compared to age-matched controls (15%)	Results do not support an effect of cancer on pre-treatment cognition.
Von Ah D et al. [8]	Examine the frequency of clinically significant cognitive dysfunction in breast cancer survivors and possible associations with treatment	52 breast cancer survivors 52 individually matched healthy	Cases: 58.2 (9.2) Controls: 59.0 (9.0)	104	55.8% C 79% H 80.8% R 100% S	Breast cancer survivors exhibited impaired neurocognitive functioning compared to age-matched controls. Exploratory analysis	Longitudinal studies needed to examine long-term trajectory of cognitive decline

(continued on next page)

Table 1 (continued)

Authors	Study objectives	Study population	Mean age (SD, range)	N ^a	Treatments	Main study findings	Comments
		controls				showed no association between exposure to chemo or hormonal therapy and neurocognitive function	
Case-control							
Koppelmans V et al. [33]	Examine if chemo is associated with worse cognitive performance in breast cancer survivors more than 20 years after treatment	196 breast cancer survivors (avg. 21.2 years since diagnosis) 1509 controls	Cases: 64.1 (6.4) Controls: 57.9 (5.4)	1705	100% C	Up to 20 years later, women exposed to chemo performed significantly worse on neurocognitive tests (memory, processing speed, executive functioning, psychomotor speed) and had greater self-reported memory impairment	Lack of baseline or interim cognitive scores limits comment on rate of decline compared to healthy controls. Longer longitudinal studies are needed to understand cognitive trajectories over time.
Prospective longitudinal							
Ahles TA et al. [42]	Examine, longitudinally, the impact of age and cognitive reserve on cognition among breast cancer patients receiving adjuvant treatment	132 breast cancer survivors: 60 treated with chemo 72 not treated with chemo 45 healthy controls	Breast cancer survivors treated with chemo: 51.7 (7.1, 31–66) Breast cancer survivors not treated with chemo: 56.6 (8.3, 37–69) Controls: 52.9 (10, 30–68)	177	Among those treated with chemo: 80% H 81% R Among those not treated with chemo: 66% H, 72% R	Breast cancer survivors showed lower scores on neurocognitive tests (processing speed and executive function) compared to healthy controls. Older survivors and those treated with chemo performed poorest. Age was related to post-treatment decline in women exposed to chemo.	Influence of cancer treatment on cognitive functioning may vary by age
Collins B et al. [43]	Examine neurocognitive outcomes in breast cancer patients pre-treatment, during treatment, and 1 year after completion of chemo	60 breast cancer patients 60 healthy, age, education, and language-matched controls	Cases: 51.8 (7.8) Controls: 51.3 (7.7)	120	100% C 84% H 100% S	48% of breast cancer survivors showed steady cognitive decline during and immediately post-chemo, with partial recovery in cognitive function (working memory) at 1 year follow-up. Higher proportion of patients (22%) showed persistent impairment at follow-up compared to the control group (6%).	A sub-set of breast cancer patients show long-term treatment-related cognitive decline. Findings provide some support for accelerated aging hypotheses
Lepage C et al. [44]	Assess relationship between grey matter attenuation via functional magnetic resonance imaging (fMRI) and neurocognitive function in breast cancer patients prior to treatment, during chemo, one month following chemo, and one year after completion of treatment	19 breast cancer survivors 19 controls	Cases: 50.2 (8.6, 35–64) Controls: 49.3 (9.0, 31–61)	38	Among cases: 100% C 52.6% H 68.4% R 100% S	Cases showed reduced grey matter volume one month post-chemo, with a partial recovery one year post-treatment. Neurocognitive testing showed similar pattern, with poorest processing speed scores one month post-treatment and some improvement at one year. These changes were not observed in controls.	Changes in brain volume observed through neuroimaging had a similar trajectory to neurocognitive deficits. Partial recovery does not support accelerated aging hypothesis
Mandelblatt JS et al. [45]	Determine long-term trajectories of self-reported cognitive function and test the effects of chemo on cognitive trajectories among older breast cancer survivors 6 months post-chemo and annually for up to 7 years	1280 breast cancer survivors	72.7 (6.6)	1280	67.6% S 40.5% C (with or without H) 53.7% H only	Through follow-up, 42.3% maintained high self-reported cognitive scores, 50.1% showed a phase shift (parallel) pattern, and 7.6% showed accelerated decline. While age was not directly related to trajectory, age-related traits (having >2 vs ≤2 comorbidities and frailty, respectively) were associated more strongly with the accelerated aging group than the phase shift group.	Cognitive impairment in breast cancer survivors varies and may result from the complex interaction of age, cancer treatment, and cancer itself.
Schagen SB et al. [46]	Assess the effects of high vs. standard dose chemo on cognitive function up to 12 months post-treatment	124 breast cancer patients 60 healthy controls	Cases: High dose: 45.2 (5.8) Standard dose: 45.5 (6.6) No chemo:	184	High dose: 22.6% (100% H) Standard dose: 31.5% (97% H)	Greater proportion of high-dose chemo patients, compared to controls, exhibited deterioration of cognitive functioning over time. No difference for standard dose or controls	Results support the notion that breast cancer survivors treated with high-dose chemo may experience accelerated cognitive decline compared to controls

Table 1 (continued)

Authors	Study objectives	Study population	Mean age (SD, range)	N ^a	Treatments	Main study findings	Comments
Schilder CM et al. [47]	Examine the influence of tamoxifen and exemestane on cognitive functioning 1 year post-treatment in postmenopausal breast cancer patients	179 breast cancer patients:80 tamoxifen 99 exemestane 120 healthy controls	50.5 (7.7) Controls: 48.8 (6) Cases: Tamoxifen: 68.7 (7.6, 51–84) Exemestane: 68.3 (6.8, 50–82) Controls: 66.2 (7.9, 49–86)	299	Tamoxifen: 100% H 58.8% R 100% S Exemestane: 100% H 20.2% R 100% S	At one year, compared to controls, those treated with tamoxifen showed cognitive impairments, while exemestane group did not. Among tamoxifen group, older survivors (> 65 yrs) showed greater deficits than younger survivors (≤ 65 yrs)	Tamoxifen may be associated with persistent decline and effects may be age-dependent

Acronyms: C- Chemotherapy H- Hormonal therapy. R- Radiation therapy. S- Surgery.

^a N = number of study participants.

chemotherapy. Compared to a matched cohort of healthy women, MRI scans of breast cancer survivors demonstrate an initial reduction in grey matter volume, which tends to improve by one year post-treatment. Neuropsychological tests revealed that the grey matter changes correlated with some level of cognitive impairment, specifically in the processing speed domain [81].

3. Molecular Mechanisms of Normal Cellular Aging in Patients with Breast Cancer

The pathology behind cancer cells and aging is most simply defined as the accumulation of cellular damage; whereas cancerous mutations provide advantages in certain cells for growth, cellular damage causes loss of fitness in aging cells. We use cytotoxic treatments to inhibit tumor growth; however, this treatment is indiscriminate and also affects the non-tumor cells. Describing the cellular and molecular hallmarks of aging including: 1) telomere attrition; 2) mitochondrial dysfunction; 3) genomic instability; 4) epigenetic alterations; and 5) cellular senescence, we discuss how each may be affected in the setting of normal aging versus breast cancer and its related treatments.

3.1. Telomere Attrition

Telomeres are particularly prone to age-related DNA damage [82] and most somatic cells do not express telomerase, limiting their ability to replicate the terminal ends of chromosomes [83]. Thus, telomere de-protection and shortening have been cited as a Hallmark of Aging [2]. In patients with breast cancer, the treatments given could contribute to accelerated aging at least in part by its effects on telomeres [84]. One recent systematic review of telomere length (TL) included 33 studies that reported on TL measured in blood, tumor and normal tissues in relation to prognostic factors [85]. The authors reported that with the exception of one negative study, there was an overall trend toward a positive association of longer telomeres in breast tissue with a better prognosis. It was notable that in peripheral blood, blood TL was not associated with chemotherapy in three out of four studies [85]. Apart from TL, telomere deprotection mechanisms are potentiated by anti-mitotic therapies such as colcemid, vinblastine, Taxol, and Velcade [86].

3.2. Cellular Energetics

Declines in mitochondrial function and corresponding somatic mtDNA mutations have been reported in normal human aging [87, 88]. Specifically, insulin/IGF-1 and rapamycin (TOR) signaling pathways that regulate cellular aging have been linked to dysfunctional mitochondria [89–91]. How cancer therapies affect cellular energetics as they relate to rate of aging is unclear, but mitochondrial energetics appear to play an important role in cancer metabolism and growth. Somatic

mitochondrial DNA alterations allow cancer cells to adapt to the tumor microenvironment of hypoxic and acidic conditions, and some have proposed a mechanism of metabolic coupling between cancer cells and stromal cells. Tumor cells induce reprogramming in surrounding non-tumor cells to undergo mitophagy, reducing the number of mitochondria, resulting in conversion to glycolytic metabolism (the Warburg phenotype). These stromal fibroblasts generate excessive lactate and ketones; producing fuel for anabolic cancer cells ('reverse Warburg') [92, 93]. Additionally, mitochondrial dysfunction may promote breast cancer malignancy as dysregulated mitochondria may affect oncogenic regulation by elevated ROS, decreased apoptosis and resistance to chemotherapeutic agents [94–96].

3.3. Genome Instability

Genome instability is a hallmark of cancer and it is also a hallmark of aging, as DNA damage accumulates in normal cells over time, primarily through endogenous processes such as replication errors and reactive oxygen species-induced DNA damage [3]. Many of the cytotoxic chemotherapies used to treat cancer, including microtubule poisons, alkylating agents, anti-metabolites, topoisomerase inhibitors and DNA cross-linking agents, as well as radiation therapy, are designed to kill tumor cells by causing lethal DNA damage. Indeed, these exogenous agents also damage DNA in normal cells, but the presence of intact tumor suppressive checkpoints and competent DNA repair pathways in non-cancer cells, as well as their generally lower proliferation rate, usually result in preferential tumor cell death. However, these treatments greatly accelerate the rate of nuclear and mitochondrial DNA damage, also synergizing with endogenous mechanisms of DNA damage such as elevated ROS levels, potentially contributing to accelerated aging [97, 98].

3.4. Epigenetic Alterations

Epigenetic alterations are also likely to contribute to the aging phenotype, and may be accelerated in breast cancer survivors. Sehl et al. have examined the breast tissue and peripheral blood of 40 patients with breast cancer and found that breast cancer tissue had a higher epigenetic age, with the difference diminishing with advancing chronological age [99]. Certainly, changes in DNA methylation, post-translational modification of histones, and alterations of chromatin remodeling complexes are characteristic of aging [100], and could potentially be impacted by cancer treatment. Although some of the key regulators of these processes have begun to be identified, including DNA and histone methylases and demethylases, histone acetylases and de-acetylases and chromatin remodelers, how they regulate the changes in aging through alteration of global transcriptional programs, remains to be elucidated.

3.5. Suppressor Checkpoints for Cellular Senescence

In normal tissues, the p16^{INK4A}/Rb and p19^{ARF}/p53 pathways are two critical regulatory pathways that are usually suppressed, but become activated to prevent cells with damaged DNA from replicating [101, 102]. In cancer cells, one or both of these pathways is commonly disrupted, enabling tumor cells bearing markedly damaged DNA to proliferate. These dysregulated pathways can be targeted by cytotoxic chemotherapies, resulting in preferential cell death of tumor cells, but how these treatments also affect normal cells with intact p16^{INK4A}/Rb and p19^{ARF}/p53 pathways is unclear.

DNA damage accumulates over the lifespan with a corresponding increase of p16^{INK4A}/Rb and p19^{ARF}/p53 noted with advancing chronological age [103]. In breast cancer survivors, including those undergoing cytotoxic chemotherapy, the levels of p16 and p19, potential biomarkers of accelerated aging, are markedly increased and the extent of accelerated aging was calculated to be equivalent to 14.7 years of chronological aging [104]. Additionally, p16^{INK4A} expression at later time points found that the increased levels of p16^{INK4A} persisted for at least several years after initial chemotherapy exposure [104].

3.6. Other Markers of Cellular Senescence

In one longitudinal study of 315 women, 209 were diagnosed and treated for breast cancer and 106 were diagnosed with benign disease. At baseline there were no differences in cellular senescence or comorbidities; however, after follow-up of eighteen months, patients with breast cancer treated with surgery, radiation, and chemotherapy had elevated IL-6 and tumor necrosis factor- α levels as compared to controls [105]. Importantly, compared to controls, there was a significant increase in comorbidities in survivors, who were treated with multimodal therapy, suggesting that they may be at highest risk of accelerated aging and comorbidity development.

4. Concluding Remarks

Integrated DNA, RNA, epigenetic and immunohistochemical analyses [106–110] are reshaping the understanding of the molecular underpinnings of breast cancer. Increasingly sophisticated molecular classification systems are emerging [111] that promise to further improve outcomes by helping match the right patient with the right drug or combination of drugs. This is welcome news for women with breast cancer; however, as they survive, they experience an array of health challenges that need to be better understood. In addition to the risk of developing second malignancies that could be related to germline vulnerabilities or post-treatment effects, survivors experience chronic health problems characteristic of accelerated aging [112], including chemotherapy related amenorrhea, decreased cardiorespiratory fitness, increased risk of fracture, osteoporosis and neuropathy, and cognitive decline which can persist for months to years following treatment [33, 113].

As more women become long-term breast cancer survivors, the accumulated toll of treatment-induced damage to normal cells becomes increasingly significant. In this review, we have highlighted five of nine previously described cellular hallmarks of aging that have been described in the context of cytotoxic breast cancer treatments [2]. The biology of aging in itself is an active area of investigation and understanding how perturbations such as cytotoxic therapies affect the rate of aging could lead to the development of novel therapeutics. As an example, p16^{INK4A} is now being used a biomarker of chemotherapy toxicity to identify chemotherapy induced senescent (TIS) cells [114]. With development of blood-based biomarkers, new senolytic drugs, such as ABT-263, have shown promise in human cells and mouse studies by selectively eliminating TIS, leading to better outcomes such as reduced bone marrow suppression and less cardiac toxicity [114, 115].

By solving the problem of immediate survival for the vast majority of patients with breast cancer we now face new challenges. Scientists and clinicians together should make efforts to combine their expertise so that each can be aware of the emerging technologies in the context of real live patient experiences. Ideally, longitudinal mechanistic studies should be designed to identify the molecular basis of accelerated cancer aging in tandem with assessing clinically important outcomes so that interventions can be developed to maximize therapy anti-tumor effects while also optimizing the long-term health of breast cancer survivors.

Contributions

Study conception: Chang L, Jeste D, Kado D; Study design: Chang L, Kado D; Data acquisition and quality control: Chang L, Weiner L, Hartman S, Kado D; Data analysis and interpretation: Chang L, Weiner L, Hartman S, Mischel P, Horvath S, Kado D; Statistical analysis: N/A; Manuscript preparation, editing and review: All authors.

Conflicts of Interest

The authors have no conflicts of interest to declare.

References

- [1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. *CA Cancer J Clin* 2017;67(1): 7–30 Epub 2017/01/06 <https://doi.org/10.3322/caac.21387>. (PubMed PMID: 28055103).
- [2] López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. *Cell* 2013;153(6):1194–217. <https://doi.org/10.1016/j.cell.2013.05.039> (PubMed PMID: 23746838; PMCID: PMC3836174).
- [3] Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell* 2011;144(5):646–74. <https://doi.org/10.1016/j.cell.2011.02.013> (PubMed PMID: 21376230).
- [4] Reimer T, Gerber B. Quality-of-life considerations in the treatment of early-stage breast cancer in the elderly. *Drugs Aging* 2010;27(10):791–800. <https://doi.org/10.2165/11584700-000000000-00000> (PubMed PMID: 20883059).
- [5] Cohen HJ, Lan L, Archer L, Kornblith AB. Impact of age, comorbidity and symptoms on physical function in long-term breast cancer survivors (CALGB 70803). *J Geriatr Oncol* 2012;3(2). <https://doi.org/10.1016/j.jgo.2012.01.005> (82–9). (PubMed PMID: 22707996; PMCID: PMC3375059).
- [6] Smith AW, Alfano CM, Reeve BB, Irwin ML, Bernstein L, Baumgartner K, Bowen D, McTiernan A, Ballard-Barbash R. Race/ethnicity, physical activity, and quality of life in breast cancer survivors. *Cancer Epidemiol Biomarkers Prev* 2009;18(2): 656–63. <https://doi.org/10.1158/1055-9965.EPI-08-0352> (PubMed PMID: 19190157; PMCID: PMC3031117).
- [7] Wampler MA, Topp KS, Miaskowski C, Byl NN, Rugo HS, Hamel K. Quantitative and clinical description of postural instability in women with breast cancer treated with taxane chemotherapy. *Arch Phys Med Rehabil* 2007;88(8):1002–8. <https://doi.org/10.1016/j.apmr.2007.05.007> (PubMed PMID: 17678662).
- [8] Von Ah D, Russell KM, Stormiolo AM, Carpenter JS. Cognitive dysfunction and its relationship to quality of life in breast cancer survivors. *Oncol Nurs Forum* 2009; 36(3):326–34 (PubMed PMID: 44460586).
- [9] Paraskevi T. Quality of life outcomes in patients with breast cancer. *Oncol Rev* 2012;6(1). <https://doi.org/10.4081/oncol.2012.e2> (PubMed PMID: 25992204; PMCID: PMC4419638).
- [10] Rowland JH, Bellizzi KM. Cancer survivorship issues: life after treatment and implications for an aging population. *J Clin Oncol* 2014;32(24):2662–8. <https://doi.org/10.1200/jco.2014.55.8361> (PubMed PMID: 25071099).
- [11] Ciambone D. Treatment decision-making among older women with breast cancer. *J Women Aging* 2006;18(4):31–47. https://doi.org/10.1300/J074v18n04_04.
- [12] Puts MTE, Tapscott B, Fitch M, Howell D, Monette J, Wan-Chow-Wah D, Krzyzanowska M, Leighl NB, Springall E, Alibhai SM. A systematic review of factors influencing older adults' decision to accept or decline cancer treatment. *Cancer Treat Rev* 2015;41(2):197–215. <https://doi.org/10.1016/j.ctrv.2014.12.010>.
- [13] Turner KM, Deshpande V, Beyter D, Koga T, Rusert J, Lee C, Li B, Arden K, Ren B, Nathanson DA, Kornblum HI, Taylor MD, Kaushal S, Cavenee WK, Wechsler-Reya R, Furnari FB, Vandenberg SR, Rao PN, Wahl GM, Bafna V, Mischel PS. Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity. *Nature* 2017;543(7643):122–5 Epub 2017/02/09 <https://doi.org/10.1038/nature21356>. (PubMed PMID: 28178237; PMCID: PMC5334176).
- [14] Tidwell TR, Soreide K, Hagland HR. Aging, Metabolism, and Cancer Development: from Peto's Paradox to the Warburg Effect. *Aging Dis* 2017;8(5):662–76 Epub 2017/10/03 <https://doi.org/10.14336/AD.2017.0713>. (PubMed PMID: 28966808; PMCID: PMC5614328).
- [15] de Magalhaes JP. How ageing processes influence cancer. *Nat Rev Cancer* 2013;13(5):357–65 Epub 2013/04/25 <https://doi.org/10.1038/nrc3497>. (PubMed PMID: 23612461).
- [16] Torino F, Barnabei A, De Vecchis L, Sini V, Schittulli F, Marchetti P, Corsello SM. Chemotherapy-induced ovarian toxicity in patients affected by endocrine-responsive

- early breast cancer. *Crit Rev Oncol Hematol* 2014;89(1):27–42. <https://doi.org/10.1016/j.critrevonc.2013.07.007> (PubMed PMID: 23953684).
- [17] Shadyab AH, Macera CA, Shaffer RA, Jain S, Gallo LC, Gass ML, Waring ME, Stefanick ML, Lacroix AZ. Ages at menarche and menopause and reproductive lifespan as predictors of exceptional longevity in women: the Women's Health Initiative. *Menopause* 2017;24(1):35–44. <https://doi.org/10.1097/GME.0000000000000710> (PubMed PMID: 27465713; PMCID: PMC5177476).
 - [18] Peel AB, Thomas SM, Dittus K, Jones LW, Lakoski SG. Cardiorespiratory fitness in breast cancer patients: a call for normative values. *J Am Heart Assoc* 2014;3(1):e000432. <https://doi.org/10.1161/JAHA.113.000432> (PubMed PMID: 24419734; PMCID: PMC3959685).
 - [19] Zambetti M, Moliterni A, Materazzo C, Stefanelli M, Cipriani S, Valagussa P, Bonadonna G, Gianni L. Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation. *J Clin Oncol* 2001;19(1):37–43 (PubMed PMID: 11134193).
 - [20] Ganz PA, Husey MA, Moynour CM, Unger JM, Hutchins LF, Dakhil SR, Giguere JK, Goodwin JW, Martino S, Albain KS. Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol s8897. *J Clin Oncol* 2008;26(8):1223–30. <https://doi.org/10.1200/JCO.2007.11.8877> (PubMed PMID: 18227530).
 - [21] Doyle JJ, Neugut AI, Jacobson JS, Grann VR, Hershman DL. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. *J Clin Oncol* 2005;23(34):8597–605. <https://doi.org/10.1200/JCO.2005.02.5841> (PubMed PMID: 16314622).
 - [22] Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N, Sawyer DB. Anthracycline cardiotoxicity: from bench to bedside. *J Clin Oncol* 2008;26(22):3777–84. <https://doi.org/10.1200/JCO.2007.14.9401> (PubMed PMID: 18669466; PMCID: PMC3018290).
 - [23] Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. *J Clin Oncol* 2007;25(25):3808–15. <https://doi.org/10.1200/JCO.2006.10.4976> (PubMed PMID: 17664460).
 - [24] Bouvard B, Soulié P, Hoppé E, Georin-Mege M, Royer M, Mesgouez-Nebout N, Lassalle C, Cellier P, Jadaud E, Abadie-Lacourtoisie S, Tuchsais C, Vinchon-Petit S, Audran M, Chappard D, Legrand E. Fracture incidence after 3 years of aromatase inhibitor therapy. *Ann Oncol* 2014;25(4):843–7. <https://doi.org/10.1093/annonc/mdu008> (PubMed PMID: 24608193).
 - [25] Vanderwalde A, Hurria A. Aging and osteoporosis in breast and prostate cancer. *A Cancer J Clin* 2011;61(3):139–56. <https://doi.org/10.3322/caac.20103> (PubMed PMID: 201105522. Language: English. Entry Date: 20110715. Revision Date: 20120302. Publication Type: journal article. Journal Subset: Biomedical).
 - [26] Brufsky AM. Cancer treatment-induced bone loss: pathophysiology and clinical perspectives. *Oncologist* 2008;13(2):187–95. <https://doi.org/10.1634/theoncologist.2007-0152> (PubMed PMID: 18305064).
 - [27] Balducci L. Bone complications of cancer treatment in the elderly. *Oncology (Williston Park)* 2010;24(8):741–7 (PubMed PMID: 20718254).
 - [28] Ward PR, Wong MD, Moore R, Naem A. Fall-related injuries in elderly cancer patients treated with neurotoxic chemotherapy: a retrospective cohort study. *J Geriatr Oncol* 2014;5(1):57–64 Epub 2013/11/08 <https://doi.org/10.1016/j.jgo.2013.10.002>. (PubMed PMID: 24484719).
 - [29] Vardy J. Cognitive function in breast cancer survivors. *Cancer Treat Res* 2009;151:387–419. https://doi.org/10.1007/978-0-387-75115-3_24 (PubMed PMID: 19593525).
 - [30] Janelins MC, Kesler SR, Ahles TA, Morrow GR. Prevalence, mechanisms, and management of cancer-related cognitive impairment. *Int Rev Psychiatry* 2014;26(1):102–13. <https://doi.org/10.3109/09540261.2013.864260> (PubMed PMID: 24716504; PMCID: PMC4084673).
 - [31] Wefel JS, Kesler SR, Noll KR, Schagen SB. Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults. *CA Cancer J Clin* 2015;65(2):123–38. <https://doi.org/10.3322/caac.21258> (PubMed PMID: 25483452; PMCID: PMC4355212).
 - [32] Ahles TA, Root JC, Ryan EL. Cancer- and cancer treatment-associated cognitive change: an update on the state of the science. *J Clin Oncol* 2012;30(30):3675–86 Epub 2012/09/26 <https://doi.org/10.1200/jco.2012.43.0116>. (PubMed PMID: 23008308; PMCID: PMC3675678).
 - [33] Koppelmans V, Breteler MM, Boogerd W, Seynaeve C, Gundy C, Schagen SB. Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy. *J Clin Oncol* 2012;30(10):1080–6 Epub 2012/03/01 <https://doi.org/10.1200/jco.2011.37.0189>. (PubMed PMID: 22370315).
 - [34] Wefel JS, Saleeba AK, Buzdar AU, Meyers KA. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. *Cancer* 2010;116(14):3348–56 Epub 2010/06/22 <https://doi.org/10.1002/cncr.25098>. (PubMed PMID: 20564075).
 - [35] Conroy SK, McDonald BC, Smith DJ, Moser LR, West JD, Kamendulis LM, Klaunig JE, Champion VL, Unverzagt FW, Saykin AJ. Alterations in brain structure and function in breast cancer survivors: effect of post-chemotherapy interval and relation to oxidative DNA damage. *Breast cancer research and treatment*. 2013;137(2):493–502. doi: <https://doi.org/10.1007/s10549-012-2385-x>. (PubMed PMID: 23263697; PMCID: PMC3543695).
 - [36] de Ruiter MB, Reneman L, Boogerd W, Veltman DJ, van Dam FSAM, Nederveen AJ, Boven E, Schagen SB. Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer. *Hum Brain Mapp* 2011;32(8):1206–19. <https://doi.org/10.1002/hbm.21102>.
 - [37] Kesler SR, Kent JS, O'Hara R. Prefrontal cortex and executive function impairments in primary breast cancer. *Arch Neurol* 2011;68. <https://doi.org/10.1001/archneurol.2011.245>.
 - [38] Kesler SR, Watson CL, Blayney DW. Brain network alterations and vulnerability to simulated neurodegeneration in breast cancer. *Neurobiol Aging* 2015;36(8):2429–42. <https://doi.org/10.1016/j.neurobiolaging.2015.04.015> (PubMed PMID: 26004016; PMCID: PMC4464941).
 - [39] Lange M, Giffard B, Noal S, Rigal O, Kurtz J-E, Heutte N, Lévy C, Allouache D, Rieux C, Fel JL, Daireaux A, Clarisse B, Veyret C, Barthélémy P, Longato N, Eustache F, Joly F. Baseline cognitive functions among elderly patients with localised breast cancer. *Eur J Cancer* 2014;50(13):2181–9. <https://doi.org/10.1016/j.ejca.2014.05.026>.
 - [40] Mandelblatt JS, Stern RA, Luta G, McGuckin M, Clapp JD, Hurria A, Jacobsen PB, Faul LA, Isaacs C, Denduluri N, Gavett B, Traina TA, Johnson P, Silliman RA, Turner RS, Howard D, Meter JWV, Saykin A, Ahles T. Cognitive impairment in older patients with breast cancer before systemic therapy: is there an interaction between cancer and comorbidity? *J Clin Oncol* 2014;32(18):1909–18. <https://doi.org/10.1200/jco.2013.54.2050> (PubMed PMID: 24841981).
 - [41] Von Ah D. Cognitive function in breast cancer survivors compared to healthy age- and education-matched women. 2009;23(4):661–74. <https://doi.org/10.1080/13854040802541439> (PubMed PMID: 19156566; PMCID: PMC3557514).
 - [42] Ahles TA, Saykin AJ, McDonald BC, Li Y, Furstenberg CT, Hanscom BS, Mulrooney TJ, Schwartz GN, Kaufman PA. Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. *J Clin Oncol* 2010;28(29):4434–40 Epub 2010/09/15 <https://doi.org/10.1200/jco.2009.27.0827>. (PubMed PMID: 20837957; PMCID: PMC2988635).
 - [43] Collins B, MacKenzie J, Tasca GA, Scherling C, Smith A. Persistent cognitive changes in breast cancer patients 1 year following completion of chemotherapy. *J Int Neuropsychol Soc* 2013;20(4):370–9 Epub 11/15 <https://doi.org/10.1017/S1355617713001215>.
 - [44] Lepage C, Smith AM, Moreau J, Barlow-Krelina E, Wallis N, Collins B, MacKenzie J, Scherling C. A prospective study of grey matter and cognitive function alterations in chemotherapy-treated breast cancer patients. *SpringerPlus* 2014;3(1):444. <https://doi.org/10.1186/2193-1801-3-444>.
 - [45] Mandelblatt JS, Clapp JD, Luta G, Faul LA, Tallarico MD, McClendon TD, Whitley JA, Cai L, Ahles TA, Stern RA, Jacobsen PB, Small BJ, Pitcher BN, Dura-Fernandis E, Muss HB, Hurria A, Cohen HJ, Isaacs C. Long-term trajectories of self-reported cognitive function in a cohort of older survivors of breast cancer: CALGB 369901 (Alliance). *Cancer* 2016;122(22):3555–63. <https://doi.org/10.1002/cncr.30208>.
 - [46] Schagen SB, Muller MJ, Boogerd W, Mellenbergh GJ, van Dam FS. Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients. *J Natl Cancer Inst* 2006;98. <https://doi.org/10.1093/jnci/djj470>.
 - [47] Schilder CM, Seynaeve C, Beex LV, Boogerd W, Linn SC, Gundy CM, Huizenga HM, Nortier JW, van de Velde CJ, van Dam FS, Schagen SB. Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. *J Clin Oncol* 2010;28(8):1294–300. <https://doi.org/10.1200/JCO.2008.21.3553> (PubMed PMID: 20142601).
 - [48] Jim HS, Phillips KM, Chait S, Faul LA, Papa MA, Lee YH, Hussin MG, Jacobsen PB, Small BJ. Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. *J Clin Oncol* 2012;30(29):3578–87 Epub 2012/08/29 <https://doi.org/10.1200/jco.2011.39.5640>. (PubMed PMID: 22927526; PMCID: PMC3462044).
 - [49] Falletti MG, Sanfilippo A, Maruff P, Weih L, Phillips KA. The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. *Brain Cogn* 2005;59(1):60–70 (PubMed PMID: 15975700).
 - [50] Anderson-Hanley C, Sherman ML, Riggs R, Agocha VB, Compas BE. Neuropsychological effects of treatments for adults with cancer: a meta-analysis and review of the literature. *J Int Neuropsychol Soc* 2003;9(7):967–82 Epub 2004/01/24 <https://doi.org/10.1017/s1355617703970019>. (PubMed PMID: 14738279).
 - [51] Jansen CE, Miskowski C, Dodd M, Dowling G, Kramer J. A meta-analysis of studies of the effects of cancer chemotherapy on various domains of cognitive function. *Cancer* 2005;104(10):2222–33 Epub 2005/10/06 <https://doi.org/10.1002/cncr.21469>. (PubMed PMID: 16206292).
 - [52] Jansen CE, Cooper BA, Dodd MJ, Miskowski CA. A prospective longitudinal study of chemotherapy-induced cognitive changes in breast cancer patients. *Support Care Cancer* 2011;19(10):1647–56 Epub 2010/09/08 <https://doi.org/10.1007/s00520-010-0997-4>. (PubMed PMID: 20820813).
 - [53] Ono M, Ogilvie JM, Wilson JS, Green HJ, Chambers SK, Ownsworth T, Shum DH. A meta-analysis of cognitive impairment and decline associated with adjuvant chemotherapy in women with breast cancer. *Front Oncol* 2015;5:59. <https://doi.org/10.3389/fonc.2015.00059> (PubMed PMID: 25806355; PMCID: PMC4354286).
 - [54] Jenkins V, Shilling V, Deutsch G, Bloomfield D, Morris R, Allan S, Bishop H, Hodson N, Mitra S, Sadler G, Shah E, Stein R, Whitehead S, Winstanley J. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. *Br J Cancer* 2006;94(6):828–34 Epub 2006/03/09 <https://doi.org/10.1038/sj.bjc.6603029>. (PubMed PMID: 16523200; PMCID: PMC3216421).
 - [55] Tager FA, McKinley PS, Schnabel FR, El-Tamer M, Cheung YK, Fang Y, Golden CR, Frosch ME, Habib U, Mulligan MM, Chen IS, Hershman DL. The cognitive effects of chemotherapy in post-menopausal breast cancer patients: a controlled longitudinal study. *Breast Cancer Res Treat* 2010;123(1):25–34. <https://doi.org/10.1007/s10549-009-0606-8> (PubMed PMID: 19894112).
 - [56] Phillips KA, Ribl K, Fisher R. Do aromatase inhibitors have adverse effects on cognitive function? *Breast Cancer Res* 2011;13(1):203. <https://doi.org/10.1186/bcr2806>.
 - [57] Schilder CMT, Seynaeve C, Linn SC, Boogerd W, Beex LVAM, Gundy CM, Nortier JWR, van de Velde CJH, van Dam FSAM, Schagen SB. Self-reported cognitive functioning in postmenopausal breast cancer patients before and during endocrine treatment: findings from the neuropsychological TEAM side-study. *Psychooncology* 2012;21(5):479–87. <https://doi.org/10.1002/pon.1928>.

- [58] Castellon SA, Ganz PA, Bower JE, Petersen L, Abraham L, Greendale GA. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. *J Clin Exp Neuropsychol* 2004;26(7):955–69 Epub 2005/03/04 <https://doi.org/10.1080/13803390490510905>. (PubMed PMID: 15742545).
- [59] Merriman JD, Sereika SM, Brufsky AM, McAuliffe PF, McGuire KP, Myers JS, Phillips ML, Ryan CM, Gentry AL, Jones LD, Bender CM. Trajectories of self-reported cognitive function in postmenopausal women during adjuvant systemic therapy for breast cancer. *Psychooncology* 2017;26(1):44–52. <https://doi.org/10.1002/pon.4009>.
- [60] Phillips KA, Aldridge J, Ribi K, Sun Z, Thompson A, Harvey V, Thürlimann B, Cardoso F, Pagani O, Coates AS, Goldhirsch A, Price KN, Gelber RD, Bernhard J. Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial. *Breast Cancer Res Treat* 2011;126. <https://doi.org/10.1007/s10549-010-1235-y>.
- [61] Collins B, Mackenzie J, Stewart A, Bielajew C, Verma S. Cognitive effects of chemotherapy in post-menopausal breast cancer patients 1 year after treatment. *Psychooncology* 2009;18(2):134–43 Epub 2008/06/14 <https://doi.org/10.1002/pon.1379>. (PubMed PMID: 18551510).
- [62] Hermelink K, Untch M, Lux MP, Kreienberg R, Beck T, Bauerfeind I, Munzel K. Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. *Cancer* 2007;109. <https://doi.org/10.1002/cncr.22610>.
- [63] Ahles TA, Saykin AJ, McDonald BC, Furstenberg CT, Cole BF, Hanscom BS, Mulrooney TJ, Schwartz GN, Kaufman PA. Cognitive function in breast cancer patients prior to adjuvant treatment. *Breast Cancer Res Treat* 2008;110(1):143–52. <https://doi.org/10.1007/s10549-007-9686-5> (PubMed PMID: 17674194; PMCID: PMC3114441).
- [64] Mather M. Aging and cognition. *Wiley Interdiscip Rev Cogn Sci* 2010;1(3):346–62 Epub 2010/05/01 <https://doi.org/10.1002/wcs.64>. (PubMed PMID: 26271375).
- [65] Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the United States (2010–2050) estimated using the 2010 census. *Neurology* 2013;80(19):1778–83 Epub 2013/02/08 <https://doi.org/10.1212/WNL.0b013e31828726f5>. (PubMed PMID: 23390181; PMCID: PMC3719424).
- [66] Lichtman SM, Hurria A, Jacobsen PB. Geriatric Oncology: An Overview. *J Clin Oncol* 2014;32(24):2521–2. <https://doi.org/10.1200/jco.2014.57.4822>.
- [67] Surveillance, Epidemiology, and End Results (SEER) Program Populations (1969–2015); 2016.
- [68] Ehlers D, Trinh L, McAuley E. The intersection of cancer and aging: implications for physical activity and cardiorespiratory fitness effects on cognition. *Expert Review of Quality of Life in Cancer Care* 2016;1(5):347–50. <https://doi.org/10.1080/23809000.2016.1241661>.
- [69] Hurria A, Rosen C, Hudis C, Zuckerman E, Panageas KS, Lachs MS, Witmer M, van Gorp WG, Fornier M, D'Andrea G, Moasser M, Dang C, Van Poznak C, Hurria A, Holland J. Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study. *J Am Geriatr Soc* 2006;54(6):925–31. Epub 2006/06/17. doi: <https://doi.org/10.1111/j.1532-5415.2006.00732.x>. PubMed PMID: 16776787.
- [70] Ahles TA, Root JC, Ryan EL. Cancer- and cancer treatment-associated cognitive change: an update on the state of the science. *J Clin Oncol* 2012;30(30):3675–86. <https://doi.org/10.1200/jco.2012.43.0116> (PubMed PMID: 23008308; PMCID: PMC3675678).
- [71] Merriman JD, Von Ah D, Miskowski C, Aouizerat BE. Proposed mechanisms for cancer- and treatment-related cognitive. *Seminars in oncology nursing*. 2013;29(4). <https://doi.org/10.1016/j.soncn.2013.08.006> (PubMed PMID: 24183157; PMCID: PMC3817493).
- [72] Mandelblatt JS, Hurria A, McDonald BC, Saykin AJ, Stern RA, Vanmeter JW, McGuckin M, Traita T, Denduluri N, Turner S, Howard D, Jacobsen PB, Ahles T. Cognitive effects of cancer and its treatments at the intersection of aging: what do we know; what do we need to know? *Semin Oncol* 2013;40(6):709–25 Epub 2013/12/18 <https://doi.org/10.1053/j.seminoncol.2013.09.006>. (PubMed PMID: 24331192; PMCID: PMC3880205).
- [73] Debess J, Riis JO, Engebjerg MC, Ewertz M. Cognitive function after adjuvant treatment for early breast cancer: a population-based longitudinal study. *Breast Cancer Res Treat* 2010;121(1):91–100 Epub 2010/03/23 <https://doi.org/10.1007/s10549-010-0756-8>. (PubMed PMID: 20306129).
- [74] Janelins MC, Heckler CE, Peppone LJ, Kamen C, Mustian KM, Mohile SG, Magnuson A, Kleckner IR, Guido JJ, Young KL, Conlin AK, Weiselberg LR, Mitchell JW, Ambrosone CA, Ahles TA, Morrow GR. Cognitive complaints in survivors of breast cancer after chemotherapy compared with age-matched controls: an analysis from a nationwide, multicenter, prospective longitudinal study. *J Clin Oncol* 2017;35(5):506–14. <https://doi.org/10.1200/jco.2016.68.5826> (PubMed PMID: 28029304).
- [75] Schagen SB, Muller MJ, Boogerd W, Mellenbergh GJ, van Dam FSAM. Change in Cognitive Function After Chemotherapy: a Prospective Longitudinal Study in Breast Cancer Patients. *JNCI* 2006;98(23):1742–5. <https://doi.org/10.1093/jnci/djj470>.
- [76] Koppelmans V, de Ruiter MB, van der Lijn F, Boogerd W, Seynaeve C, van der Lugt A, Vrooman H, Niessen WJ, Breteler MM, Schagen SB. Global and focal brain volume in long-term breast cancer survivors exposed to adjuvant chemotherapy. *Breast Cancer Res Treat* 2012;132(3):1099–106 Epub 2011/12/30 <https://doi.org/10.1007/s10549-011-1888-1>. (PubMed PMID: 22205140).
- [77] de Ruiter MB, Reneman L, Boogerd W, Veltman DJ, Caan M, Douaud G, Lavini C, Linn SC, Boven E, van Dam FS, Schagen SB. Late effects of high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: converging results from multimodal magnetic resonance imaging. *Hum Brain Mapp* 2012;33(12):2971–83 Epub 2011/11/19 <https://doi.org/10.1002/hbm.21422>. (PubMed PMID: 22095746).
- [78] Deprez S, Amant F, Yigit R, Porke K, Verhoeven J, Van den Stock J, Smeets A, Christiaens MR, Leemans A, Van Hecke V, Vandenberghe J, Vandembulcke M, Snaert S. Chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning in breast cancer patients. *Hum Brain Mapp* 2011;32(3):480–93 Epub 2010/08/21 <https://doi.org/10.1002/hbm.21033>. (PubMed PMID: 20725909).
- [79] Silverman DHS, Dy CJ, Castellon SA, Lai J, Pio BS, Abraham L, Waddell K, Petersen L, Phelps ME, Ganz PA. Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5–10 years after chemotherapy. *Breast Cancer Res Treat* 2007;103(3):303–11. <https://doi.org/10.1007/s10549-006-9380-z>.
- [80] Scherling C, Collins B, Mackenzie J, Bielajew C, Smith A. Pre-chemotherapy differences in visuospatial working memory in breast cancer patients compared to controls: an fMRI study. *Front Hum Neurosci* 2011;5:122 Epub 2011/11/05 <https://doi.org/10.3389/fnhum.2011.00122>. (PubMed PMID: 22053153; PMCID: PMC3205481).
- [81] Lepage C, Smith AM, Moreau J, Barlow-Krelina E, Wallis N, Collins B, MacKenzie J, Scherling C. A prospective study of grey matter and cognitive function alterations in chemotherapy-treated breast cancer patients. *Springerplus* 2014;3:444 Epub 2014/09/04 <https://doi.org/10.1186/2193-1801-3-444>. (PubMed PMID: 25184110; PMCID: PMC4149682).
- [82] Blackburn EH, Greider CW, Szostak JW. Telomeres and telomerase: the path from maize, Tetrahymena and yeast to human cancer and aging. *Nat Med* 2006;12(10):1133–8. <https://doi.org/10.1038/nm1006-1133> (PubMed PMID: 17024208).
- [83] Blasco MA. Telomere length, stem cells and aging. *Nat Chem Biol* 2007;3(10):640–9. <https://doi.org/10.1038/nchembio.2007.38> (PubMed PMID: 17876321).
- [84] Blackburn EH, Epel ES, Lin J. Human telomere biology: A contributory and interactive factor in aging, disease risks, and protection. *Science* 2015;350(6265):1193–8. <https://doi.org/10.1126/science.aab3389> (PubMed PMID: 26785477).
- [85] Ennou-Idrissi K, Maunsell E, Diorio C. Telomere length and breast cancer prognosis: a systematic review. *Cancer Epidemiol Biomarkers Prev* 2017;26(1):3–10 Epub 2016/09/27 <https://doi.org/10.1158/1055-9965.EPI-16-0343>. (PubMed PMID: 27677729).
- [86] Hayashi MT, Cesare AJ, Fitzpatrick JA, Lazzarini-Denchi E, Karlseder J. A telomere-dependent DNA damage checkpoint induced by prolonged mitotic arrest. *Nat Struct Mol Biol* 2012;19(4):387–94 Epub 2012/03/11 <https://doi.org/10.1038/nsmb.2245>. (PubMed PMID: 22407014; PMCID: PMC3319806).
- [87] Bratic A, Larsson NG. The role of mitochondria in aging. *J Clin Invest* 2013;123(3):951–7 Epub 2013/03/05 <https://doi.org/10.1172/JCI61425>. (PubMed PMID: 23454757; PMCID: PMC3582127).
- [88] Kravtsov Y, Kudryavtseva E, McKee AC, Geula C, Kowall NW, Khrapko K. Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. *Nat Genet* 2006;38(5):518–20 Epub 2006/04/11 <https://doi.org/10.1038/ng1778>. PubMed PMID: 16604072.
- [89] Ryan MT, Hoogenraad NJ. Mitochondrial-nuclear communications. *Annu Rev Biochem* 2007;76:701–22 Epub 2007/01/18 <https://doi.org/10.1146/annurev.biochem.76.052305.091720>. (PubMed PMID: 17227225).
- [90] Holzenberger M, Dupont J, Ducos B, Leneuve P, Gélöën A, Even PC, Cervera P, Le Bouc Y. IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. *Nature* 2003;421(6919):182–7. <https://doi.org/10.1038/nature01298> (PubMed PMID: 12483226).
- [91] Bonawit ND, Chatenay-Lapointe M, Pan Y, Shadel GS. Reduced TOR signaling extends chronological life span via increased respiration and upregulation of mitochondrial gene expression. *Cell Metab* 2007;5(4):265–77 Epub 2007/04/04 <https://doi.org/10.1016/j.cmet.2007.02.009>. (PubMed PMID: 17403371; PMCID: PMC3460550).
- [92] Pavlides S, Whitaker-Menezes D, Castello-Cros R, Flomenberg N, Witkiewicz AK, Frank PG, Casimiro MC, Wang C, Fortina P, Addya S, Pestell RG, Martinez-Outschoorn UE, Sotgia F, Lisanti MP. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. *Cell Cycle* 2009;8(23):3984–4001 Epub 2009/11/20 <https://doi.org/10.4161/cc.8.23.10238>. (PubMed PMID: 19923890).
- [93] Bonuccelli G, Whitaker-Menezes D, Castello-Cros R, Pavlides S, Pestell RG, Fatatis A, Witkiewicz AK, Vander Heiden MG, Migneco G, Chiavarina B, Frank PG, Capozza F, Flomenberg N, Martinez-Outschoorn UE, Sotgia F, Lisanti MP. The reverse Warburg effect: glycolysis inhibitors prevent the tumor promoting effects of caveolin-1 deficient cancer associated fibroblasts. *Cell Cycle* 2010;9(10):1960–71 Epub 2010/05/25 <https://doi.org/10.4161/cc.9.10.11601>. (PubMed PMID: 20495363).
- [94] Elliott RL, Jiang XP, Head JF. Mitochondria organelle transplantation: introduction of normal epithelial mitochondria into human cancer cells inhibits proliferation and increases drug sensitivity. *Breast Cancer Res Treat* 2012;136(2):347–54 Epub 2012/10/20 <https://doi.org/10.1007/s10549-012-2283-2>. (PubMed PMID: 23080556).
- [95] Ma J, Zhang Q, Chen S, Fang B, Yang Q, Chen C, Miele L, Sarkar FH, Xia J, Wang Z. Mitochondrial dysfunction promotes breast cancer cell migration and invasion through HIF1alpha accumulation via increased production of reactive oxygen species. *PLoS One* 2013;8(7):e69485 Epub 2013/08/08 <https://doi.org/10.1371/journal.pone.0069485>. (PubMed PMID: 23922721; PMCID: PMC3726697).
- [96] Kaiparettu BA, Ma Y, Park JH, Lee TL, Zhang Y, Yotnda P, Creighton CJ, Chan WY, Wong LJ. Crosstalk from non-cancerous mitochondria can inhibit tumor properties of metastatic cells by suppressing oncogenic pathways. *PLoS One* 2013;8(5):e61747 Epub 2013/05/15 <https://doi.org/10.1371/journal.pone.0061747>. (PubMed PMID: 23671572; PMCID: PMC3650012).

- [97] Stolarek RA, Potargowicz E, Seklewska E, Jakubik J, Lewandowski M, Jeziorski A, Nowak D. Increased H₂O₂ level in exhaled breath condensate in primary breast cancer patients. *J Cancer Res Clin Oncol* 2010;136(6):923–30. <https://doi.org/10.1007/s00432-009-0734-x> (PubMed PMID: 19967414).
- [98] Ray G, Batra S, Shukla NK, Deo S, Raina V, Ashok S, Husain SA. Lipid peroxidation, free radical production and antioxidant status in breast cancer. *Breast Cancer Res Treat* 2000;59(2):163–70 (PubMed PMID: 10817351).
- [99] Sehl ME, Henry JE, Stomiolo AM, Ganz PA, Horvath S. DNA methylation age is elevated in breast tissue of healthy women. *Breast Cancer Res Treat* 2017;164(1):209–19 Epub 2017/03/31 <https://doi.org/10.1007/s10549-017-4218-4>. (PubMed PMID: 28364215; PMCID: PMC5487725).
- [100] Oberdoerffer P, Sinclair DA. The role of nuclear architecture in genomic instability and ageing. *Nat Rev Mol Cell Biol* 2007;8(9):692–702. <https://doi.org/10.1038/nrm2238> (PubMed PMID: 17700626).
- [101] Vandenberg B, Brouwers B, Hatse S, Wildiers H. p16INK4a: A central player in cellular senescence and a promising aging biomarker in elderly cancer patients. *J Geriatr Oncol* 2011;2(4):259–69. <https://doi.org/10.1016/j.jgo.2011.08.004>.
- [102] Liu Y, Sanoff HK, Cho H, Burd CE, Torrice C, Ibrahim JG, Thomas NE, Sharpless NE. Expression of p16(INK4a) in peripheral blood T-cells is a biomarker of human aging. *Aging Cell* 2009;8(4):439–48. <https://doi.org/10.1111/j.1474-9726.2009.00489.x> (PubMed PMID: 19485966; PMCID: PMC2752333).
- [103] Krishnamurthy J, Torrice C, Ramsey MR, Kovalev GI, Al-Regaiey K, Su L, Sharpless NE. Ink4a/Arf expression is a biomarker of aging. *J Clin Invest* 2004;114(9):1299–307. <https://doi.org/10.1172/JCI22475> (PubMed PMID: 15520862; PMCID: PMC524230).
- [104] Sanoff HK, Deal AM, Krishnamurthy J, Torrice C, Dillon P, Sorrentino J, Ibrahim JG, Jolly TA, Williams G, Carey LA, Drobish A, Gordon BB, Alston S, Hurria A, Kleinhans K, Rudolph KL, Sharpless NE, Muss HB. Effect of cytotoxic chemotherapy on markers of molecular age in patients with breast cancer. *J Natl Cancer Inst* 2014;106(4):dju057. <https://doi.org/10.1093/jnci/dju057> (PubMed PMID: 24681605; PMCID: PMC3982894).
- [105] Alfano CM, Peng J, Andridge RR, Lindgren ME, Povoski SP, Lipari AM, Agnese DM, Farrar WB, Yee LD, Carson WE, Kiecolt-Glaser JK. Inflammatory cytokines and comorbidity development in breast cancer survivors versus noncancer controls: evidence for accelerated aging? *J Clin Oncol* 2017;35(2):149–56 Epub 2016/11/28 <https://doi.org/10.1200/JCO.2016.67.1883>. (PubMed PMID: 27893337; PMCID: PMC5455675).
- [106] Perou CM, Sørli T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. *Nature* 2000;406(6797):747–52. <https://doi.org/10.1038/35021093> (PubMed PMID: 10963602).
- [107] van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R. A gene-expression signature as a predictor of survival in breast cancer. *N Engl J Med* 2002;347(25):1999–2009. <https://doi.org/10.1056/NEJMoa021967> (PubMed PMID: 12490681).
- [108] van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH. Gene expression profiling predicts clinical outcome of breast cancer. *Nature* 2002;415(6871):530–6. <https://doi.org/10.1038/415530a> (PubMed PMID: 11823860).
- [109] Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. *N Engl J Med* 2004;351(27):2817–26. <https://doi.org/10.1056/NEJMoa041588> (PubMed PMID: 15591335).
- [110] Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, Wilson C, Rong HM, Bauerfeind I, Felber M, Wang HJ, Beryt M, Seshadri R, Hepp H, Slamon DJ. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. *J Natl Cancer Inst* 2003;95(2):142–53 (PubMed PMID: 12529347).
- [111] Dawson SJ, Rueda OM, Aparicio S, Caldas C. A new genome-driven integrated classification of breast cancer and its implications. *EMBO J* 2013;32(5):617–28. <https://doi.org/10.1038/emboj.2013.19> (PubMed PMID: 23395906; PMCID: PMC3590990).
- [112] Henderson TO, Ness KK, Cohen HJ. Accelerated aging among cancer survivors: from pediatrics to geriatrics. *Am Soc Clin Oncol Educ Book* 2014:e423–30. https://doi.org/10.14694/EdBook_AM.2014.34.e423 (PubMed PMID: 24857133).
- [113] Berger AM, Gerber LH, Mayer DK. Cancer-related fatigue: implications for breast cancer survivors. *Cancer* 2012;118(8 Suppl):2261–9. <https://doi.org/10.1002/cncr.27475> (PubMed PMID: 22488700).
- [114] Demaria M, O'Leary MN, Chang J, Shao L, Liu S, Alimirah F, Koenig K, Le C, Mitin N, Deal AM, Alston S, Academia EC, Kilmarx S, Valdovinos A, Wang B, de Bruin A, Kennedy BK, Melov S, Zhou D, Sharpless NE, Muss H, Campisi J. Cellular senescence promotes adverse effects of chemotherapy and cancer relapse. *Cancer Discov* 2017;7(2):165–76 Epub 2016/12/17 <https://doi.org/10.1158/2159-8290.CD-16-0241>. (PubMed PMID: 27979832; PMCID: PMC5296251).
- [115] Chang J, Wang Y, Shao L, Laberge RM, Demaria M, Campisi J, Janakiraman K, Sharpless NE, Ding S, Feng W, Luo Y, Wang X, Aykin-Burns N, Krager K, Ponnappan U, Hauer-Jensen M, Meng A, Zhou D. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. *Nat Med* 2016;22(1):78–83 Epub 2015/12/15 <https://doi.org/10.1038/nm.4010>. (PubMed PMID: 26657143; PMCID: PMC4762215).